Product Overview
NexGard is a veterinary product formulated as a chewable tablet to protect dogs from fleas and ticks. Each tablet contains Afoxolaner, an active ingredient that provides effective and long-lasting control of these external parasites. NexGard is a convenient and palatable option for dog owners, ensuring hassle-free administration and reliable protection for their pets.
Uses
NexGard is indicated for the treatment and prevention of flea infestations and the control of tick infestations in dogs. It kills adult fleas before they can lay eggs, preventing further infestations in the environment. Additionally, NexGard eliminates multiple species of ticks, including black-legged ticks, American dog ticks, and brown dog ticks, reducing the risk of tick-borne diseases in dogs.
How to Use
Administer NexGard chewable tablets orally to your dog as directed by your veterinarian. Offer the tablet directly to your dog or mix it with food for easy consumption. Ensure your dog consumes the entire dose. For optimal efficacy, administer NexGard at regular intervals to maintain continuous protection against fleas and ticks.
How it Works
Afoxolaner, the active ingredient in NexGard, belongs to the isoxazoline class of compounds, which acts on the nervous system of fleas and ticks. It works by targeting specific receptors in the parasites’ nervous system, leading to their paralysis and death. NexGard starts killing fleas within 2 hours and ticks within 8 hours after administration, providing rapid relief for your dog.
Dosage and Administration
The dosage of NexGard chewable tablets is based on your dog’s weight and is available in different strengths to accommodate various sizes of dogs. Administer the appropriate dosage as prescribed by your veterinarian. For optimal efficacy, give NexGard to your dog with a full meal. Ensure your dog consumes the entire tablet, and do not divide the dose into smaller portions.
Benefits
- Effective protection against fleas and ticks for up to 30 days
- Chewable formulation for easy administration and palatability
- Rapid onset of action kills fleas within 2 hours and ticks within 8 hours
- Helps prevent the transmission of tick-borne diseases to dogs
- Suitable for use in puppies as young as 8 weeks of age and weighing at least 4 pounds
Common Side Effects
Common side effects associated with NexGard may include mild gastrointestinal upset, such as vomiting or diarrhea, in some dogs. These side effects are typically transient and resolve on their own without intervention. In rare cases, hypersensitivity reactions, including itching, redness, or swelling, may occur. If any adverse reactions persist or worsen, contact your veterinarian for further guidance.
Warnings
NexGard is for use in dogs only and should not be administered to cats or other animals. Use with caution in dogs with a history of seizures or neurological disorders. Avoid use in dogs with a known hypersensitivity to Afoxolaner or other ingredients in the formulation. Keep out of reach of children and pets to prevent accidental ingestion. If accidental ingestion occurs, seek medical attention immediately.
Storage Information
Store NexGard chewable tablets in a cool, dry place at room temperature, away from moisture and sunlight. Keep the tablets in their original packaging and ensure the container is tightly closed when not in use. Proper storage helps maintain the stability and effectiveness of the medication throughout its shelf life.
Disclaimer:
Our sole intention is to ensure that its consumers get information that is expert-reviewed, accurate, and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified veterinarian. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings or alerts. Please consult your veterinarian and discuss all your queries related to the health of your pet. We intend to support, not replace, the veterinarian-patient relationship.
Reviews
There are no reviews yet.